Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUX-Lung 8
NL-OMON38119Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) and bronchial carcinoma comparing Afatinib with Erlotinib (2 arms). Primary endpoint: Progression-free survival. Started Jul 2012; status: active, not recruiting.
02
Drugs
afatiniberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on NL-OMON38119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38119.